At our National Zoom meeting on February 3, 2021, our guest was Dr. Neil Berinstein of the Toronto Sunnybrook Hospital and Odette Cancer Research Program.  For the first time in several years, we were able to hear about a clinical trial being started in Canada.  Dr. Berinstein, the principal investigator, explained the rationale for the choice of treatments being combined in this trial.

The trial involves the Canadian “standard of care” treatment (Bendamustine plus Rituximab), combined with a one-year, time-limited use of Acalabrutinib.  The trial is described more formally at this Clinical site.

To see the video of our National Zoom meeting, you’ll need a passcode:  T0tV7$j2

(That’s a zero, not an oh, as the second character.  And if you’re trying to copy and paste, make sure you don’t have an extra space at the beginning or end.)